Company / CIK 0001840233
Xilio Therapeutics, Inc.
- Ticker
- XLO
- Size, estimated from filings
- Micro cap (under $300M)
- Insiders on file
- 14
- Federal contracts on record
- none matched
- Lobbying filings on record
- none matched
- SEC filings
- EDGAR ↗
- Latest trade on record
- October 1, 2026
Xilio Therapeutics, Inc. (XLO) has 14 insiders on file who disclosed 79 transactions in the last 12 months (2 open-market buys, 2 sales, about $12.0M at reported prices). No federal contract award that started in the last 180 days was found for a recipient with exactly this name; no lobbying filing names it as client this year.
Xilio Therapeutics, Inc. in charts
Who is trading this stock
Which people account for the buying and selling over the last 12 months?
3 people account for the disclosed buying and selling in Xilio Therapeutics, Inc. over the last 12 months; the most active is Shannon James Samuel with $44K.
Insiders
| Name | Role | Rows | Bought | Sold | Last filed |
|---|---|---|---|---|---|
| Houvras Yariv | CHIEF MEDICAL OFFICER | 1 | 0 | 0 | October 2, 2026 |
| Bello Akintunde Olatokumbo | Director | 1 | 0 | 0 | June 12, 2026 |
| Shannon James Samuel | Director | 2 | 1 | 0 | June 12, 2026 |
| Curran Daniel J. | Director | 1 | 0 | 0 | June 12, 2026 |
| Xu Yuan | Director | 1 | 0 | 0 | June 12, 2026 |
| ROSS ROBERT W. | Director | 1 | 0 | 0 | June 12, 2026 |
| Bonstein Sara | Chief Financial Officer | 1 | 0 | 0 | June 12, 2026 |
| Brennan Aoife | Director | 1 | 0 | 0 | June 12, 2026 |
| GILEAD SCIENCES, INC. | Insider | 3 | 0 | 0 | May 27, 2026 |
| Blanchard Cheryl R | Director | 1 | 0 | 0 | April 16, 2026 |
| Russo Rene | PRESIDENT AND CEO | 20 | 0 | 0 | January 5, 2026 |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | 14 | 0 | 0 | January 5, 2026 |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | 11 | 0 | 1 | January 5, 2026 |
| Frankenfield Christopher James | Chief Financial Officer | 21 | 0 | 1 | January 5, 2026 |
Rows are this company's Form 4 rows for each person. "Bought" and "sold" count open-market purchases (code P) and sales only. More in insider buying and insider selling.
Insider transactions
| Filer | Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Houvras Yariv | XLO | Other A | October 1, 2026 | October 2, 2026 | 1d | 105,000 | — | — | derivative | Form 4 ↗ | |
| Brennan Aoife | XLO | Other A | June 11, 2026 | June 12, 2026 | 1d | 5,000 | — | — | derivative | Form 4 ↗ | |
| Bonstein Sara | XLO | Other A | June 11, 2026 | June 12, 2026 | 1d | 5,000 | — | — | derivative | Form 4 ↗ | |
| ROSS ROBERT W. | XLO | Other A | June 11, 2026 | June 12, 2026 | 1d | 5,000 | — | — | derivative | Form 4 ↗ | |
| Xu Yuan | XLO | Other A | June 11, 2026 | June 12, 2026 | 1d | 5,000 | — | — | derivative | Form 4 ↗ | |
| Curran Daniel J. | XLO | Other A | June 11, 2026 | June 12, 2026 | 1d | 5,000 | — | — | derivative | Form 4 ↗ | |
| Shannon James Samuel | XLO | Other A | June 11, 2026 | June 12, 2026 | 1d | 5,000 | — | — | derivative | Form 4 ↗ | |
| Bello Akintunde Olatokumbo | XLO | Other A | June 11, 2026 | June 12, 2026 | 1d | 5,000 | — | — | derivative | Form 4 ↗ | |
| Blanchard Cheryl R | XLO | Other A | April 15, 2026 | April 16, 2026 | 1d | 10,000 | — | — | derivative | Form 4 ↗ | |
| Shannon James Samuel | XLO | Buy P | March 26, 2026 | March 30, 2026 | 4d | 5,000 | $9 | $44K | Form 4 ↗ | ||
| GILEAD SCIENCES, INC. | XLO | Option / conversion P | February 13, 2026 | February 17, 2026 | 4d | 3,739,000 | $1 | $2.0M | derivative | Form 4 ↗ | |
| Luptakova Katarina | XLO | Option / conversion M | January 1, 2026 | January 5, 2026 | 4d | 16,625 | — | — | derivative | Form 4 ↗ | |
| Luptakova Katarina | XLO | Other A | December 31, 2025 | January 5, 2026 | 5d | 451,885 | — | — | latederivative | Form 4 ↗ | |
| Luptakova Katarina | XLO | Option / conversion M | January 1, 2026 | January 5, 2026 | 4d | 16,625 | — | — | Form 4 ↗ | ||
| Brennan Kevin M. | XLO | Option / conversion M | January 1, 2026 | January 5, 2026 | 4d | 5,000 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| Brennan Kevin M. | XLO | Other A | December 31, 2025 | January 5, 2026 | 5d | 95,221 | — | — | late10b5-1 planderivative | Form 4 ↗ | |
| Brennan Kevin M. | XLO | Sell S | January 2, 2026 | January 5, 2026 | 3d | 1,826 | $1 | $1,174 | 10b5-1 plan | Form 4 ↗ | |
| Brennan Kevin M. | XLO | Option / conversion M | January 1, 2026 | January 5, 2026 | 4d | 5,000 | — | — | 10b5-1 plan | Form 4 ↗ | |
| Frankenfield Christopher James | XLO | Option / conversion M | January 1, 2026 | January 5, 2026 | 4d | 19,375 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| Frankenfield Christopher James | XLO | Other A | December 31, 2025 | January 5, 2026 | 5d | 668,789 | — | — | late10b5-1 planderivative | Form 4 ↗ | |
| Frankenfield Christopher James | XLO | Sell S | January 2, 2026 | January 5, 2026 | 3d | 7,030 | $1 | $4,522 | 10b5-1 plan | Form 4 ↗ | |
| Frankenfield Christopher James | XLO | Option / conversion M | January 1, 2026 | January 5, 2026 | 4d | 19,375 | — | — | 10b5-1 plan | Form 4 ↗ | |
| Russo Rene | XLO | Option / conversion M | January 1, 2026 | January 5, 2026 | 4d | 44,250 | — | — | derivative | Form 4 ↗ | |
| Russo Rene | XLO | Other A | December 31, 2025 | January 5, 2026 | 5d | 1,500,258 | — | — | latederivative | Form 4 ↗ | |
| Russo Rene | XLO | Option / conversion M | January 1, 2026 | January 5, 2026 | 4d | 44,250 | — | — | Form 4 ↗ | ||
| GILEAD SCIENCES, INC. | XLO | Option / conversion X | November 26, 2025 | December 1, 2025 | 5d | 13,335,000 | — | — | latederivative | Form 4 ↗ | |
| GILEAD SCIENCES, INC. | XLO | Option / conversion X | November 26, 2025 | December 1, 2025 | 5d | 13,335,000 | $1 | $10.0M | latederivative | Form 4 ↗ | |
| Frankenfield Christopher James | XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 300,000 | — | — | derivative | Form 4 ↗ | |
| Frankenfield Christopher James | XLO | Option / conversion D | November 21, 2025 | November 25, 2025 | 4d | 300,000 | — | — | derivative | Form 4 ↗ | |
| Frankenfield Christopher James | XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 150,000 | — | — | derivative | Form 4 ↗ | |
| Frankenfield Christopher James | XLO | Option / conversion D | November 21, 2025 | November 25, 2025 | 4d | 150,000 | — | — | derivative | Form 4 ↗ | |
| Frankenfield Christopher James | XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 117,000 | — | — | derivative | Form 4 ↗ | |
| Frankenfield Christopher James | XLO | Option / conversion D | November 21, 2025 | November 25, 2025 | 4d | 117,000 | — | — | derivative | Form 4 ↗ | |
| Frankenfield Christopher James | XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 20,000 | — | — | derivative | Form 4 ↗ | |
| Frankenfield Christopher James | XLO | Option / conversion D | November 21, 2025 | November 25, 2025 | 4d | 20,000 | — | — | derivative | Form 4 ↗ | |
| Frankenfield Christopher James | XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 45,000 | — | — | derivative | Form 4 ↗ | |
| Frankenfield Christopher James | XLO | Option / conversion D | November 21, 2025 | November 25, 2025 | 4d | 45,000 | — | — | derivative | Form 4 ↗ | |
| Frankenfield Christopher James | XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 37,296 | — | — | derivative | Form 4 ↗ | |
| Frankenfield Christopher James | XLO | Option / conversion D | November 21, 2025 | November 25, 2025 | 4d | 37,296 | — | — | derivative | Form 4 ↗ | |
| Frankenfield Christopher James | XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 23,786 | — | — | derivative | Form 4 ↗ | |
| Frankenfield Christopher James | XLO | Option / conversion D | November 21, 2025 | November 25, 2025 | 4d | 23,786 | — | — | derivative | Form 4 ↗ | |
| Frankenfield Christopher James | XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 155,090 | — | — | derivative | Form 4 ↗ | |
| Frankenfield Christopher James | XLO | Option / conversion D | November 21, 2025 | November 25, 2025 | 4d | 155,090 | — | — | derivative | Form 4 ↗ | |
| Frankenfield Christopher James | XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 925,000 | — | — | derivative | Form 4 ↗ | |
| Brennan Kevin M. | XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 20,000 | — | — | derivative | Form 4 ↗ | |
| Brennan Kevin M. | XLO | Option / conversion D | November 21, 2025 | November 25, 2025 | 4d | 20,000 | — | — | derivative | Form 4 ↗ | |
| Brennan Kevin M. | XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 25,000 | — | — | derivative | Form 4 ↗ | |
| Brennan Kevin M. | XLO | Option / conversion D | November 21, 2025 | November 25, 2025 | 4d | 25,000 | — | — | derivative | Form 4 ↗ | |
| Brennan Kevin M. | XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 55,000 | — | — | derivative | Form 4 ↗ | |
| Brennan Kevin M. | XLO | Option / conversion D | November 21, 2025 | November 25, 2025 | 4d | 55,000 | — | — | derivative | Form 4 ↗ | |
| Brennan Kevin M. | XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 131,700 | — | — | derivative | Form 4 ↗ | |
| Luptakova Katarina | XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 106,000 | — | — | derivative | Form 4 ↗ | |
| Luptakova Katarina | XLO | Option / conversion D | November 21, 2025 | November 25, 2025 | 4d | 106,000 | — | — | derivative | Form 4 ↗ | |
| Luptakova Katarina | XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 25,000 | — | — | derivative | Form 4 ↗ | |
| Luptakova Katarina | XLO | Option / conversion D | November 21, 2025 | November 25, 2025 | 4d | 25,000 | — | — | derivative | Form 4 ↗ | |
| Luptakova Katarina | XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 35,000 | — | — | derivative | Form 4 ↗ | |
| Luptakova Katarina | XLO | Option / conversion D | November 21, 2025 | November 25, 2025 | 4d | 35,000 | — | — | derivative | Form 4 ↗ | |
| Luptakova Katarina | XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 15,000 | — | — | derivative | Form 4 ↗ | |
| Luptakova Katarina | XLO | Option / conversion D | November 21, 2025 | November 25, 2025 | 4d | 15,000 | — | — | derivative | Form 4 ↗ | |
| Luptakova Katarina | XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 44,210 | — | — | derivative | Form 4 ↗ | |
| Luptakova Katarina | XLO | Option / conversion D | November 21, 2025 | November 25, 2025 | 4d | 44,210 | — | — | derivative | Form 4 ↗ | |
| Luptakova Katarina | XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 625,000 | — | — | derivative | Form 4 ↗ | |
| Russo Rene | XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 700,000 | — | — | derivative | Form 4 ↗ | |
| Russo Rene | XLO | Option / conversion D | November 21, 2025 | November 25, 2025 | 4d | 700,000 | — | — | derivative | Form 4 ↗ | |
| Russo Rene | XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 350,000 | — | — | derivative | Form 4 ↗ | |
| Russo Rene | XLO | Option / conversion D | November 21, 2025 | November 25, 2025 | 4d | 350,000 | — | — | derivative | Form 4 ↗ | |
| Russo Rene | XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 150,000 | — | — | derivative | Form 4 ↗ | |
| Russo Rene | XLO | Option / conversion D | November 21, 2025 | November 25, 2025 | 4d | 150,000 | — | — | derivative | Form 4 ↗ | |
| Russo Rene | XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 100,000 | — | — | derivative | Form 4 ↗ | |
| Russo Rene | XLO | Option / conversion D | November 21, 2025 | November 25, 2025 | 4d | 100,000 | — | — | derivative | Form 4 ↗ | |
| Russo Rene | XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 50,041 | — | — | derivative | Form 4 ↗ | |
| Russo Rene | XLO | Option / conversion D | November 21, 2025 | November 25, 2025 | 4d | 50,041 | — | — | derivative | Form 4 ↗ | |
| Russo Rene | XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 135,134 | — | — | derivative | Form 4 ↗ | |
| Russo Rene | XLO | Option / conversion D | November 21, 2025 | November 25, 2025 | 4d | 135,134 | — | — | derivative | Form 4 ↗ | |
| Russo Rene | XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 473,334 | — | — | derivative | Form 4 ↗ | |
| Russo Rene | XLO | Option / conversion D | November 21, 2025 | November 25, 2025 | 4d | 473,334 | — | — | derivative | Form 4 ↗ | |
| Russo Rene | XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 239,703 | — | — | derivative | Form 4 ↗ | |
| Russo Rene | XLO | Option / conversion D | November 21, 2025 | November 25, 2025 | 4d | 239,703 | — | — | derivative | Form 4 ↗ | |
| Russo Rene | XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 2,075,000 | — | — | derivative | Form 4 ↗ |
Federal contracts (USAspending, awards started in the last 180 days)
No contract award starting in the last 180 days was found for a recipient named exactly "Xilio Therapeutics, Inc.". Subsidiaries and differently-spelled recipients are not matched — search contracts.
Lobbying (Senate LDA, as client)
No LDA filing posted since October 2025 names "Xilio Therapeutics, Inc." as the client. Filings under a subsidiary or trade-association name are not matched — search lobbying.
Related companies
Companies whose stock was traded by the same people who traded XLO, by number of filers in common. It shows overlap in public filings and nothing else.
- INSMED Inc INSM 1 filer in common
- ASSEMBLY BIOSCIENCES, INC. ASMB 1 filer in common
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 20 | 79 | November 25, 2025 | October 2, 2026 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Insiders and their transactions come from SEC EDGAR Form 4 filings for this issuer. Contracts and lobbying are matched by exact normalized name (suffixes like Inc./Corp. ignored) to USAspending recipients and LDA clients — a conservative match that misses subsidiaries on purpose. See methodology and corrections.
Not investment advice. Public records shown as filed; no recommendation is made or implied.